Halitosis in COVID‐19 patients
Abstract
Dear Editor, Halitosis is a reflective condition for an array of systemic insults such as respiratory, otolaryngologic and gastrointestinal pathologies that may alter salivary characteristics and tongue dorsum susceptibility for hosting anaerobic microorganisms. The high prevalence of halitosis globally requires a multidisciplinary approach for its diagnosis, assessment and treatment to discriminate between genuine, pseudoand denied halitosis based on subjective metrics.1 As with other circulating pandemics, halitosis has been greatly challenged by the outbreak of the coronavirus disease (COVID-19), and a few confirmed cases were reported to present with halitosis while being actively infected.2 We hereby aim to report according to the CARE guidelines, the demographic, clinical and laboratory characteristics of eighteen patients with confirmed COVID-19 without any relevant medical history, who experienced new-onset halitosis during their course of infection.3 The referenced patients sought care at our department between May and August 2020 due to an offensive oral malodour that precipitated notable psychosocial distress, especially with their spouses. All patients had previously undergone polymerase chain reaction (PCR) testing for severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) for various reasons, for instance: before-travel screening (22.2%), after-travel screening (27.8%), being in contact with a positive case (22.2%), presenting with mild symptoms such as…
Read the paper
Related studies
- Challenges and opportunities with drug repurposing: finding strategies to find alternative uses of therapeutics
- Challenges in Chagas Disease Drug Development
- T Cell Specificity: A Great Challenge in Chagas Disease
- Benznidazole treatment leads to DNA damage in Trypanosoma cruzi and the persistence of rare widely dispersed non-replicative amastigotes in mice
- Rapid Molecular Detection of Terbinafine-resistant Dermatophytes
- Identifying novel drugs with new modes of action for neglected tropical fungal skin diseases (fungal skinNTDs) using an Open Source Drug discovery approach
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.